We are providing rapid, highly accurate COVID diagnostics to those who need it most.
In partnership with QIAGEN®, Ellume has accelerated the development of a rapid, reliable COVID test to support the global response to the coronavirus pandemic. The QIAGEN Access Anti-SARS-CoV-2 Total, is a high-performance serological test which detects antibodies in people who have been exposed to SARS-CoV-2.
The test has received an Emergency Use Authorization (EUA) from the US FDA, with CE-IVD marking anticipated in the coming weeks.
Sensitivity of 100% (CI 88.43–100.00%)
Specificity of 100% (CI 95.20–100.00%)
Key Features
| ● Early positive results from 3 minutes
● Simple testing process ● Minimal training requirements ● Single patient visit ● Objective automated test result ● No calibration or maintenance required ● No cold chain required ● No continuous power supply required ● No computer access required |
Coronavirus: The Facts
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. COVID-19 is a respiratory illness primarily spread from person to person. COVID-19 symptoms can range from mild (or no symptoms) to severe illness. There are currently more than 21 million* confirmed cases globally with >775,000 deaths*. With no specific vaccines or treatments currently available for COVID-19, rapid diagnosis is pivotal to minimising transmission.
* Last update: 20 August 2020 – https://www.who.int/emergencies/diseases/novel-coronavirus-2019